Hypoglycemic APIs are a class of compounds designed to control and treat diabetes, a chronic metabolic disease characterized by hyperglycemia. Protheragen provides a full range of anti-diabetic APIs, covering biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibition agents and glucagon-like peptide 1 (GLP-1) receptor agonists, etc. These compounds work through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.